Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 18Phase 1/2 7Phase 3 3Phase 4 1

Status

Active not recruiting 7Recruiting 5Completed 3Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × niraparib × Clear all
NCT04475939 2026-05-01

ZEAL-1L

GlaxoSmithKline

Phase 3 Completed
666 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03598270 2024-08-30

ANITA

Grupo Español de Investigación en Cáncer de Ovario

Phase 3 Completed
417 enrolled
Gynecologic

Ovarian Neoplasms

NCT01847274 2023-06-02

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Tesaro, Inc.

Phase 3 Completed
596 enrolled 65 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡